About the Authors
- Dag Tidemalm
-
* E-mail: dag.tidemalm@ki.se
Affiliation Department of Clinical Neuroscience, Center for Psychiatric Research, Karolinska Institutet, Stockholm, Sweden
- Axel Haglund
-
Affiliation Department of Clinical Neuroscience, Center for Psychiatric Research, Karolinska Institutet, Stockholm, Sweden
- Alina Karanti
-
Affiliation Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Sweden
- Mikael Landén
-
Affiliations Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Sweden, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
- Bo Runeson
-
Affiliation Department of Clinical Neuroscience, Center for Psychiatric Research, Karolinska Institutet, Stockholm, Sweden
Competing Interests
ML has, over the past 36 months, received compensation for lectures from AstraZeneca, Bayer, Biophausia, Bristol Myers-Squibb, Lundbeck Pharmaceuticals, Eli Lilly Sweden, Wyeth, Servier Sweden, and served at advisory board for AstraZeneca and Lundbeck pharmaceuticals. AK has, over the past 36 months, received compensation for lectures from Eli Lilly Sweden. BR has, over the past 36 months, received compensation for lectures from AstraZeneca, Lundbeck Pharmaceuticals, and Eli Lilly Sweden. The other authors have nothing to disclose. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: BR ML DT. Performed the experiments: DT. Analyzed the data: DT AH AK ML BR. Contributed reagents/materials/analysis tools: ML DT. Wrote the paper: DT AH AK ML BR.